319
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy

, , , , , , , , , , & show all
Pages 2677-2680 | Received 20 Aug 2015, Accepted 03 Feb 2016, Published online: 01 Mar 2016

References

  • Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer. 2011;105:1684–1692.
  • Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2011. Bethesda (MD): National Cancer Institute; 2013.
  • Link BK, Brooks J, Wright K, et al. Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma. 2011;52:994–1002.
  • Shikama N, Oguchi M, Isobe K, et al. A prospective study of reduced-dose three-course CHOP followed by involved-field radiotherapy for patients 70 years old or more with localized aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2006;66:217–222.
  • Bonnet C, Fillet G, Mournier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Grouped’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2007;25:787–792.
  • Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258–2263.
  • Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–1831.
  • Charlson ME, Pompei P, Ales K, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
  • Lin TL, Kuo MC, Shih LY, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2012;91:1383–1391.
  • Jelicic J, Todorovic Balint M. Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B cell lymphoma treated by immunochemotherapy. Neoplasma. 2015;62:988–995.
  • Miller TP, LeBlanc M, Spier CM, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin’s lymphoma: update of the southwest oncology group (SWOG) randomized trial. Blood. 2001;98:724 (Abstract).
  • Morrison VA, Hmalin P, Souberyran P, et al. Approach to therapy of diffuse large b-cell lymphoma in the elderly: the international society of geriatric oncology (SIOG) expert position commentary. Ann Oncol. 2015;26:1058–1068.
  • Campbell BA, Connors JM, Gascoyne RD, et al. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer. 2012;118:4156–4165.
  • Illidge T, Specht L, Yahalom J, et al. International Lymphoma Radiation Oncology Group. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2014;89:49–58.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.